国产99热精品_欧美疯狂做受xxxx猛交_婷婷在线网站_日韩无遮挡毛片_欧美高清momspuss_欧美激情福利

美國ImaginAb
ImaginAb 是一間私營的生物技術公司，其致力于發展以特殊設計的抗體為基礎之新式標靶診斷成像技術。ImaginAb將治療用抗體改造為PK最佳化后的惰性片段，以制造出新式體內診斷成像技術用的試劑。ImaginAb提供其商業服務給生物制藥公司，并正在努力發展針對癌癥與自體免疫疾病使用的分子成像產品。

ImaginAb is a privately held U.S. biotechnology company based in Los Angeles, CA, focused on re-engineering antibodies into smaller protein formats with kinetics optimized for diagnostic imaging.

The company has two business units. Firstly, we have a superb pipeline of clinical imaging agents for oncology and immunology. There are many unmet clinical diagnostic needs in cancer and autoimmune diseases and this is reflected in our portfolio. Our two lead products for prostate cancer and pancreatic cancer commence clinical trials in 2012.

Our second major business segment is through our pharma partnering program. ImaginAb currently has over a dozen collaborations with global pharmaceutical companies to develop bespoke companion imaging agents based on therapeutic antibody pipelines. Our technology enables a therapeutic mAb or ADC to be re-engineered into an imaging agent that has all the biospecificity of the “parent” product but with kinetics suitable for clinical imaging with low-cost isotopes. This is a transformative technology for patient selection, monitoring treatment response and “indication scouting.”

The company was founded in October 2007 by Anna Wu, Rob Reiter, Chris Behrenbruch and Tove Olafsen. The company’s scientific and clinical origins are UCLA and the City of Hope (Duarte, CA). In March 2012, ImaginAb announced that the company closed $12.5m in financing led by Novartis Venture Fund (NVF).